studies

408A AASLD ABSTRACTS HEPATOLOGY, October, 2015
RFA vs. 52.5% in HR (p=0.677). On 3cm < size ≤ 5cm, cumulative
DFS were 29.6% in TACE and RFA vs. 40.7% in HR
(p=0.513). Most common complication on both group was
elevation of AST/ALT (grade 2), most severe complication were
happened 3 cases of HR group. One is severely elevated bilirubin
without encephalopathy; the others were death due to
renal failure or sepsis. In TACE with RFA group, liver segmental
infarction were happened in 2 cases. Conclusions: Combined
TACE and RFA could be alternative choice of initial treatment
in early HCC patients.
Disclosures:
Kwan Soo Byun - Grant/Research Support: Gilead, BMS
The following authors have nothing to disclose: Young Kul Jung, Sang Jun Suh,
Hyung Joon Yim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim, Ji
Hoon Kim, Jong Eun Yeon, Yeon Seok Seo, Soon Ho Um, Ho Sang Ryu
392
Myeloid-derived suppressor cells correlate with patient
outcomes in hepatic arterial infusion chemotherapy for
hepatocellular carcinoma
Eishiro Mizukoshi, Tatsuya Yamashita, Kuniaki Arai, Takeshi Terashima,
Masaaki Kitahara, Hidetoshi Nakagawa, Noriho Iida,
Kazumi Fushimi, Shuichi Kaneko; Kanazawa Univ, Kanazawa,
Japan
Background: The modulation of tumor-associated host immune
responses after cancer treatments has recently been reported.
For example, hepatocellular carcinoma (HCC) treatments with
radiofrequency ablation or transarterial chemoembolization
were found to increase the frequency of tumor-associated antigen
(TAA)-specific T cells due to the creation of an antigen
source by the destruction of tumor cells. In addition, recent
studies demonstrated that beyond their direct cytotoxic effects
on cancer cells, several conventional chemotherapeutic drugs
promoted the elimination or inactivation of regulatory T cells
(Tregs) or myeloid-derived suppressor cells (MDSCs), resulting
in enhanced host antitumor immunity. Hepatic arterial infusion
chemotherapy (HAIC) has been employed as an alternative
therapy to sorafenib for the patients with advanced HCC in
Japan and other Asian countries. In the present study, we
performed a comparative analysis of various immune cell
responses including TAA-specific T cells, Tregs and MDSCs in
advanced HCC patients treated with HAIC, and analyzed the
relationship between these immune cell responses and patient
prognosis. Methods: Thirty-six HLA-A24-positive patients who
had clinically diagnosed advanced HCC were examined in the
present study. After being diagnosed, all patients were treated
with HAIC using interferon (IFN)/ 5-fluorouracil (FU) or IFN/
FU + cisplatin. Interferon gamma ELISPOT assays were performed
to examine the frequency of TAA-specific T cells using
11 peptides derived from 5 TAAs. The frequencies of Tregs and
MDSCs were examined by multicolor fluorescence-activated
cell sorting analysis and analyzed the association with clinical
factors and prognosis of patients. Results: The frequency of
Tregs was significantly decreased after HAIC but no significant
differences were observed in the frequency of TAA-specific T
cells and MDSCs. An analysis of prognostic factors for overall
survival identified diameter of the tumor (